VA Finds Protein That Could Transform Melanoma Treatment

Veterans battling melanoma may soon have a powerful new weapon in their fight against one of the military's most dangerous service-connected cancers.

Researchers at the William S. Middleton VA Medical Center in Madison, Wisconsin, have identified a protein called SIRT6 that acts like a fuel switch for melanoma cells. When they turned it off using advanced gene-editing techniques, cancer growth slowed dramatically and cells began dying off.

The February 2026 study, published in the journal Cancers, used two different genetic methods to silence SIRT6 in human melanoma cells. Both approaches produced the same encouraging result: cancer cells grew slower and struggled to survive.

The research team used advanced molecular mapping to understand exactly what was happening. Lowering SIRT6 levels shut down the signals that help melanoma spread while activating pathways that kill cancer cells naturally.

This matters enormously for the veteran community. Melanoma is now a presumptive condition under the PACT Act, meaning the VA assumes it's service-connected for veterans with qualifying toxic exposures. From burn pits in Iraq and Afghanistan to Agent Orange in Vietnam to contaminated water at Camp Lejeune, multiple pathways have linked military service to this aggressive skin cancer.

Current melanoma treatments have improved survival rates, but many patients develop resistance or see the cancer return. That's the gap this research aims to fill: a new target for therapy when existing options fail.

The Bright Side

The Madison VA team has been studying SIRT6's role in skin cancer for years, building a strong scientific foundation. While SIRT6-targeted treatments won't reach patients immediately, this research establishes proof that the protein is a valid target worth pursuing.

For the nearly 20 million veterans enrolled in VA healthcare, advances like this represent something profound. The same system treating their service-connected conditions is also discovering the cures of tomorrow.

Veterans currently battling melanoma have more support than ever before. The VA provides presumptive service connection for all melanomas regardless of location, including rare forms affecting the eyes and internal tissues. During active treatment, many veterans receive a 100% disability rating worth nearly $4,000 monthly in 2026.

Beyond the science, this research sends a clear message: the veterans who served in toxic environments aren't being forgotten. Their sacrifices are driving innovation that could help millions of cancer patients worldwide.

The path from laboratory discovery to bedside treatment takes years, but every breakthrough starts with studies exactly like this one.